KR102696518B1 - 글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도 - Google Patents

글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도 Download PDF

Info

Publication number
KR102696518B1
KR102696518B1 KR1020207011414A KR20207011414A KR102696518B1 KR 102696518 B1 KR102696518 B1 KR 102696518B1 KR 1020207011414 A KR1020207011414 A KR 1020207011414A KR 20207011414 A KR20207011414 A KR 20207011414A KR 102696518 B1 KR102696518 B1 KR 102696518B1
Authority
KR
South Korea
Prior art keywords
glp1
ser
val
gly
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207011414A
Other languages
English (en)
Korean (ko)
Other versions
KR20200054303A (ko
Inventor
양 웨이
하루카 오카모토
예스퍼 그로마다
사무엘 데이비스
앤드류 제이. 머피
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20200054303A publication Critical patent/KR20200054303A/ko
Application granted granted Critical
Publication of KR102696518B1 publication Critical patent/KR102696518B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
KR1020207011414A 2017-09-22 2018-09-21 글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도 Active KR102696518B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562283P 2017-09-22 2017-09-22
US62/562,283 2017-09-22
PCT/US2018/052110 WO2019060653A1 (en) 2017-09-22 2018-09-21 GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF

Publications (2)

Publication Number Publication Date
KR20200054303A KR20200054303A (ko) 2020-05-19
KR102696518B1 true KR102696518B1 (ko) 2024-08-21

Family

ID=63799082

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011414A Active KR102696518B1 (ko) 2017-09-22 2018-09-21 글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도

Country Status (14)

Country Link
US (4) US11045522B2 (enExample)
EP (1) EP3684793A1 (enExample)
JP (2) JP7239566B2 (enExample)
KR (1) KR102696518B1 (enExample)
CN (2) CN111108117B (enExample)
AU (2) AU2018338178B2 (enExample)
CA (1) CA3073964A1 (enExample)
EA (1) EA202090649A1 (enExample)
IL (2) IL273253B2 (enExample)
MX (1) MX2020002977A (enExample)
MY (2) MY200364A (enExample)
SG (1) SG11202001637PA (enExample)
WO (1) WO2019060653A1 (enExample)
ZA (1) ZA202001167B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202001637PA (en) * 2017-09-22 2020-03-30 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
WO2022119076A1 (ko) * 2020-12-03 2022-06-09 이뮤노포지 주식회사 Glp-1 수용체 작용제 및 항-오스카 항체를 포함하는 융합 단백질 및 이의 용도
WO2022117044A1 (en) * 2020-12-03 2022-06-09 Sunshine Lake Pharma Co., Ltd. Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof
CN112716966B (zh) * 2021-02-03 2022-05-03 浙江诺得药业有限公司 一种恩格列净药用组合物及其制备方法
CN113461785B (zh) * 2021-04-13 2022-10-14 湖南中晟全肽生化有限公司 Glp-1受体激动剂及其应用
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
CN114788876B (zh) * 2022-02-24 2024-07-05 北京医院 治疗糖尿病的mRNA药物制剂及其制备方法与应用
EP4520350A1 (en) * 2022-05-04 2025-03-12 ImmunoForge Co., Ltd. Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US20250270274A1 (en) * 2024-02-26 2025-08-28 Serpentide Inc. Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE525395T1 (de) 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
AR064623A1 (es) 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
WO2009020802A2 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
JP5476304B2 (ja) 2007-09-05 2014-04-23 ノボ・ノルデイスク・エー／エス グルカゴン様ペプチド−１誘導体及びそれらの医薬用途
JP2012511586A (ja) 2008-12-10 2012-05-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 医薬組成物
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
JP5774595B2 (ja) 2009-10-28 2015-09-09 ヤンセン バイオテツク，インコーポレーテツド 抗ｇｌｐ−１ｒ抗体及びそれらの使用
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
HK1207097A1 (en) 2012-09-07 2016-01-22 Sanofi Fusion proteins for treating a metabolic syndrome
JP6445459B2 (ja) 2013-01-17 2018-12-26 ブイティーブイ・セラピューティクス・エルエルシー Ｇｌｐ１ｒアゴニストとメトホルミンの組合わせおよび２型糖尿病その他の障害の処置のためのその使用
US20150259416A1 (en) 2014-03-12 2015-09-17 Biocrine Ab Methods for treating and/or limiting development of diabetes
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN104098702B (zh) * 2014-07-23 2017-06-16 湖北工业大学 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用
CN111388680B (zh) * 2015-01-28 2024-01-05 中国科学院天津工业生物技术研究所 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物
AU2016218759B2 (en) 2015-02-11 2021-11-25 Gmax Biopharm Llc. Stabilized solution preparation of pharmaceutical GLP-1R antibody fusion protein
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN109195984A (zh) * 2016-06-09 2019-01-11 免疫医疗有限公司 蛋白酶抗性的单-脂化肽
SG11202001637PA (en) 2017-09-22 2020-03-30 Regeneron Pharma Glucagon-like peptide 1 receptor agonists and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229610B1 (ko) * 2009-10-09 2013-02-05 한남대학교 산학협력단 Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hye-Shin Chung, et. al., Regulatory Peptides, 2011, vol. 170, pp. 1-3(2011.05.27.) 1부.*

Also Published As

Publication number Publication date
US20190091296A1 (en) 2019-03-28
US12090193B2 (en) 2024-09-17
CA3073964A1 (en) 2019-03-28
EA202090649A1 (ru) 2020-06-29
US20250000949A1 (en) 2025-01-02
MY200364A (en) 2023-12-21
IL304574B1 (en) 2025-04-01
US11045522B2 (en) 2021-06-29
JP7559112B2 (ja) 2024-10-01
MY207828A (en) 2025-03-21
IL304574A (en) 2023-09-01
IL304574B2 (en) 2025-08-01
US11779633B2 (en) 2023-10-10
JP2020534016A (ja) 2020-11-26
IL273253B1 (en) 2024-03-01
SG11202001637PA (en) 2020-03-30
AU2018338178B2 (en) 2023-06-08
AU2023223010B2 (en) 2025-12-04
AU2023223010A1 (en) 2023-11-09
IL273253A (en) 2020-04-30
IL273253B2 (en) 2024-07-01
US20210283225A1 (en) 2021-09-16
CN111108117B (zh) 2024-08-06
JP2024178255A (ja) 2024-12-24
AU2018338178A1 (en) 2020-04-02
JP7239566B2 (ja) 2023-03-14
CN118955732A (zh) 2024-11-15
WO2019060653A1 (en) 2019-03-28
MX2020002977A (es) 2020-11-06
CN111108117A (zh) 2020-05-05
KR20200054303A (ko) 2020-05-19
ZA202001167B (en) 2024-06-26
EP3684793A1 (en) 2020-07-29
JP2023071827A (ja) 2023-05-23
US20240024428A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
KR102696518B1 (ko) 글루카곤 유사 펩타이드 1 수용체 작용제 및 이의 용도
JP7759417B2 (ja) レプチン受容体を活性化させる抗原結合タンパク質
EP3331908B1 (en) Anti-angptl8 antibodies and uses thereof
AU2017363143B2 (en) Methods of treating obesity with anti-ANGPTL8 antibodies
EP3122776B1 (en) Fgf21 receptor agonists and uses thereof
JP2014501512A (ja) グルカゴン受容体に対するヒト抗体
US20250171516A1 (en) Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
JP7789871B2 (ja) グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
WO2025180387A1 (en) Super long-lasting glp1 or glp1/gip analogue drugfor type-2 diabetes and obesity
EA045412B1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
HK1233666B (en) Fgf21 receptor agonists and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601